Fresh Equities
Raises
Markets
About
Looking for more information?

Contact our responsive and friendly client services team any time.

(03) 9028 2888

clients@freshequities.com

ASX:OPT logo

ASX:OPT

Opthea Limited

Health Care / Biotechnology

Current price

$1.375

0.005 (0.36%)

Last trade: Invalid date GMT

Market cap

$478.03m

Market closed

Investor Presentations

Principal Activity

Opthea Limited (ASX:OPT) is a biologics drug developer focusing on ophthalmic disease therapies. It controls exclusive worldwide rights to a significant intellectual property portfolio around VEGF-C, VEGF-D and VEGFR-3. Opthea’s intellectual property is held within its wholly-owned subsidiary Vegenics Pty Ltd. Opthea’s product development programs are focused on developing OPT-302 for retinal eye diseases including wet Age-related Macular Degeneration and Diabetic Macular Edema (DME). OPT-302 is a soluble form of vascular endothelial growth factor receptor 3 (VEGFR-3) or ‘Trap’ molecule that blocks the activity of two proteins (VEGF- C and VEGF-D) that cause blood vessels to grow and leak, processes which contribute to the pathophysiology of retinal diseases. Opthea is developing OPT-302 for use in combination with inhibitors of VEGF-A and has reported outcomes from an international, multi-centre, prospective, sham-controlled, double-masked, superiority study that enrolled 366 treatment-naïve patients with wet AMD. Participants in the study were randomized in a 1:1:1 ratio to receive one of the following treatment regimens administered every 4 weeks for 24 weeks: OPT-302 (0.5 mg) in combination with ranibizumab (Lucentis®) (0.5 mg); OPT-302 (2.0 mg) in combination with ranibizumab (0.5 mg); or sham in combination with ranibizumab (0.5 mg). The study met the primary endpoint demonstrating superior vision gains in participants who received OPT-302 (2.0 mg) in combination with ranibizumab on a monthly basis over 6 months. Opthea is also investigating OPT-302 in a Phase 2a clinical trial in patients with persistent, centre-involved DME. Further details on the Company’s clinical trials can be found at: www.clinicaltrials.gov, Clinical trial identifiers: NCT02543229, NCT03345082 and NCT03397264.


Address

Unit 4/650 Chapel St, South Yarra VIC 3141, Australia

News

Announcements

Filter

All categories
Investor Presentations
Trading Halt
Qtly Cashflow
Issued Capital
Periodic Reports
AnnouncementT+2 MovementDate

Rows per page:

5

0-0 of 0

Market Data

Day

3m

1yr

5yr

Current price

$1.375

Open price

-

Day low-high

-

Price change

-

Percent change

-

Previous close

-

Volume

-

Turnover

-

Bid price

-

Ask price

-

Market cap

-

Shares outstanding

-

Year high

-

Year low

-

Year low-high

-

Earnings per share

-

Price/earnings ratio

-

Dividend yield

-

Dividend per share

-

Franking

-

Investor Presentations

News

Sector Peers

CompanyMarket Cap
Fresh Equities
App Store
Play Store

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.

Contact Us

(03) 9028 2888

clients@freshequities.com

Address

Level 19, 15 William St
Melbourne VIC 3000
Australia

App Store
Play Store

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.